First computational design using lambda-superstrings and in vivo validation of SARS-CoV-2 vaccine
dc.contributor.author | Martínez Fernández, Luis | |
dc.contributor.author | Malaina Celada, Iker | |
dc.contributor.author | Salcines Cuevas, David | |
dc.contributor.author | Terán Navarro, Héctor | |
dc.contributor.author | Zeoli, Andrea | |
dc.contributor.author | Alonso Alegre, Santos | |
dc.contributor.author | Martínez de la Fuente Martínez, Ildefonso Abel | |
dc.contributor.author | González López, Elena | |
dc.contributor.author | Ocejo Vinyals, Javier Gonzalo | |
dc.contributor.author | Gozalo Margüello, Mónica | |
dc.contributor.author | Calvo Montes, Jorge | |
dc.contributor.author | Álvarez Domínguez, Carmen | |
dc.date.accessioned | 2022-04-29T07:35:58Z | |
dc.date.available | 2022-04-29T07:35:58Z | |
dc.date.issued | 2022-04 | |
dc.identifier.citation | Scientific Reports 12 : (2022) // Article ID 6410 | es_ES |
dc.identifier.issn | 2045-2322 | |
dc.identifier.uri | http://hdl.handle.net/10810/56418 | |
dc.description.abstract | [EN] Coronavirus disease 2019 (COVID-19) is the greatest threat to global health at the present time, and considerable public and private effort is being devoted to fighting this recently emerged disease. Despite the undoubted advances in the development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, uncertainty remains about their future efficacy and the duration of the immunity induced. It is therefore prudent to continue designing and testing vaccines against this pathogen. In this article we computationally designed two candidate vaccines, one monopeptide and one multipeptide, using a technique involving optimizing lambda-superstrings, which was introducedand developed by our research group. We tested the monopeptide vaccine, thus establishing a proofofconcept for the validity of the technique. We synthesized a peptide of 22 amino acids in length, corresponding to one of the candidate vaccines, and prepared a dendritic cell (DC) vaccine vector loaded with the 22 amino acids SARS-CoV-2peptide (positions 50-71) contained in the NTD domain (DC-CoVPSA) of the Spike protein. Next, we tested the immunogenicity, thetype of immune response elicited, andthe cytokine profile induced by the vaccine, using a non-related bacterial peptide as negative control. Our results indicated that the CoVPSA peptide of the Spike protein elicits noticeable immunogenicity in vivo using a DC vaccine vector and remarkable cellular and humoral immune responses. This DC vaccine vector loaded with the NTD peptide of the Spike protein elicited a predominant Th1-Th17 cytokine profile, indicative of an effective anti-viral response. Finally, we performed a proof of concept experiment in humans that included the following groups: asymptomatic non-active COVID-19 patients, vaccinated volunteers, and control donorsthat tested negative for SARS-CoV-2. The positive controlwas the current receptor binding domain epitope of COVID-19 RNA-vaccines. We successfully developeda vaccine candidate technique involving optimizing lambda-superstringsand provided proof of concept in human subjects. We conclude thatit is a valid method to decipher the best epitopes of the Spike protein of SARS-CoV-2 to prepare peptide-based vaccines for different vector platforms, including DC vaccines. | es_ES |
dc.description.sponsorship | Luis Martínez and Iker Malaina were supported by the Basque Government, grants IT974-16 and KK-2018/00090 and by the UPV/EHU and Basque Center of Applied Mathematics, grants US18/21 and US21/27. Carmen Alvarez-Dominguez was funded by the Instituto de Salud Carlos III, grants DTS18-00022 and PI19-01580, co-funded in part with European FEDER funds “A new way of making Europe”, the Instituto de Investigación Marqués de Valdecilla, grant INNVAL20/01, and the COST European action ENOVA CA-16231. David Salcines-Cuevas was supported by a predoctoral contract for the BioHealth research program of the Cantabria government. Hector Teran-Navarro salary was supported by the Instituto de Investigación Marqués de Valdecilla, grant INNVAL19/26. Andrea Zeoli was an Erasmus student from the University of Milan “La Statale” (Milan, Italy) performing a stay at IDIVAL. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Nature Research | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.title | First computational design using lambda-superstrings and in vivo validation of SARS-CoV-2 vaccine | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | © 2022. The Author(s). This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. | es_ES |
dc.rights.holder | Atribución 3.0 España | * |
dc.relation.publisherversion | https://www.nature.com/articles/s41598-022-09615-w | es_ES |
dc.identifier.doi | 10.1038/s41598-022-09615-w | |
dc.departamentoes | Genética, antropología física y fisiología animal | es_ES |
dc.departamentoes | Matemáticas | es_ES |
dc.departamentoeu | Genetika,antropologia fisikoa eta animalien fisiologia | es_ES |
dc.departamentoeu | Matematika | es_ES |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as © 2022. The Author(s). This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.